Project Details
Projekt Print View

Humanized NSG mouse model to study combinatorial leukemogenic effects of inherited ELANE and acquired CSF3R/RUNX1 mutations in congenital neutropenia

Subject Area Hematology, Oncology
Term from 2016 to 2021
Project identifier Deutsche Forschungsgemeinschaft (DFG) - Project number 290677262
 
Final Report Year 2020

Final Report Abstract

Main conclusions: (1) We established a method of the structural prediction of the damaging effects of CN/AML- associated ELANE mutations, in order to select ELANE mutations with most “damaging” effects for the downstream analyses. (2) We developed an ultra-sensitive deep-sequencing of the CSF3R in CN and CN/AML patients in order to select positions of CSF3R mutations for downstream analysis. (3) We detected an essential role of the gene dosage of mutated RUNX1, depending of the type of mutation: a majority of CN/AML patients with missense RUNX1 mutations acquired additional trisomy 21 with two mutated RUNX1 and one WT RUNX1 alleles. At the same time, patients with truncated RUNX1 mutations had no trisomy 21. This info is essential for the experimental set-up for in vivo analyses. (4) We observed low engraftment of the gene-modified CN patients` HSPCs in NSG mice. Therefore, we performed multiple experimental attempts to improve engraftment: a) we used healthy donor cord blood cells transduced with lentivirus constructs expressing mutated ELANE; b) we developed an efficient method for CRIPSR/Cas9 gene-editing of primary human CD34+ cells with the aim to use this method for the introduction of CSF3R- and RUNX1 mutations in CB CD34+ cells expressing MUT ELANE; c) we further optimized CRISPR/Cas9 gene-editing of CD34+ cells by establishing a method of fluorescent labeling and sorting of CRPSR/Cas9-sgRNA RNP gee-edited cells. (5) First experiments of engraftment of gene-edited CD34+ cells in NSG mice show very promising results, we continue working on it. (6) In parallel to the establishment of the successful engraftment of human CD34+ cells in NSG mice, we established a mouse-mouse model of CN/AML. We used transplantation of the sublethally irradiated mice with CSF3R mutated lin-cells transduced with ELANE and RUNX1 mutation carrying consructs and treated transplanted mice or not with G-CSF. Mice developed AML or CMML within weeks after transplantation. This is the first ever in vivo model of CN/AML with very fast development of leukemia in the recipient mice. (7) We identified marked elevation of the inflammatory and innate immunity signaling pathways downstream of RUNX1 and CSF3R mutations. (8) We further studied a possible mechanism of acquisition of CSF3R and RUNX1 mutations in HSPCs of CN patients and found that HSPCs of CN patients exhibited elevated DNA damage and a strong bias towards lymphoid commitment despite G-CSF treatment. (9) We have successfully established an experimental model of step-wise leukemia development in CN using patients-derived iPSCs. Using iPSC-based model of leukemogenesis we identified deregulated signal transduction pathways along with elevated DNA damage and prolonged DNA repair in HSPCS derived from CN and CN/AML cells. (10) We demonstrated that ELANE Mutations are an ultimate genetic cause of CN.

Publications

 
 

Additional Information

Textvergrößerung und Kontrastanpassung